Investigating the Role of RPL8 Protein in Ovarian Cancer
Ruolo Delle Alterazioni Della Proteina RPL8 Nel Carcinoma Ovarico Sieroso ad Alto Grado
This study is trying to see if the RPL8 protein in ovarian cancer tumors can help doctors understand the disease better and make more informed treatment choices for patients.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 150 (estimated) |
| Ages | 18 Years and up |
| Sex | Female |
| Sponsor | IRCCS Azienda Ospedaliero-Universitaria di Bologna Academic / other |
| Locations | 1 site (Bologna, BO) |
| Trial ID | NCT06777082 on ClinicalTrials.gov |
What this trial studies
This observational study aims to explore the role of the RPL8 protein in high-grade serous ovarian carcinoma (HGSOC) by analyzing tumor tissue samples. Researchers will assess the frequency of RPL8 gene amplification and its correlation with clinical outcomes and treatment responses. The study seeks to determine if RPL8 can serve as a biomarker for risk assessment and patient stratification in therapeutic decision-making. The findings could provide new insights into the biology of HGSOC, which is often poorly understood.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older diagnosed with high-grade serous ovarian carcinoma, either at onset or recurrence.
Not a fit: Patients with ovarian tumors of histological types other than serous or those with other primary tumor types may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved risk assessment and personalized treatment options for patients with high-grade serous ovarian carcinoma.
How similar studies have performed: While the specific focus on RPL8 amplification in HGSOC is novel, similar studies investigating genetic biomarkers in ovarian cancer have shown promising results.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 years. * Diagnosis of high-grade (3 or 4) serous ovarian carcinoma, either at onset or recurrence. * Signed informed consent to participate in the study. Exclusion Criteria: * Ovarian tumors of histological types other than serous. * Other primary tumor types.
Where this trial is running
Bologna, BO
- IRCCS Azianda Ospedaliero-Universitaria di Bologna — Bologna, Bo, Italy (Recruiting)
Study contacts
- Principal investigator: Lorenzo Montanaro, MD — IRCCS Azienda Ospedaliero-Universitaria di Bologna
- Study coordinator: Lorenzo Montanaro, MD
- Email: lorenzo.montanaro@aosp.bo.it
- Phone: +390512144524
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.